已发表论文

在中国是否有 β-内酰胺类抗生素耐药的产脓链球菌出现?

 

Authors Yu D, Zheng Y, Yang Y

Received 9 May 2020

Accepted for publication 25 June 2020

Published 14 July 2020 Volume 2020:13 Pages 2323—2327

DOI https://doi.org/10.2147/IDR.S261975

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Suresh Antony

Abstract: Streptococcus pyogenes  is regarded as susceptible to β-lactam antibiotics. The guidelines of the Clinical and Laboratory Standards Institute (CLSI) are widely recognized and have long-recommended penicillin for treatment of S. pyogenes  infections. There is no CLSI guideline for the treatment of S. pyogenes  infections that have intermediate susceptibility or resistance to penicillin. However, there have been several reports of S. pyogenes  isolates that are nonsusceptible or even resistant to β-lactam antibiotics, mostly from Chinese journals. The purpose of this commentary is to show data from the literature which suggests the presence of S. pyogenes  isolates that are not susceptible to β-lactam antibiotics and whether these strains are really nonsusceptible to β-lactam antibiotics and the presence of mutation in the pbp2x  gene requires further research and confirmation.
Keywords: Streptococcus pyogenes , GAS, β-lactam, antibiotic resistance, China



Table 1 Publications Reporting the Percentages of Resistance (R) and...